AI CuratorAI-generated
Research summary · AI summary · not yet reviewedHuman studyObservationalPublished in a peer-reviewed journal
Metabolite Analysis in Humans with Multiple Sclerosis
In a cross-sectional study involving 323 people with multiple sclerosis, multiple metabolites were associated with MS severity. Notably, p-cresol sulfate and p-cresol glucuronide linked to greater disease severity, while other metabolites indicated more favorable outcomes.
- Tags
- #Biomarkers
- Most relevant to
- —
This plain-English summary was written by AI from a published abstract and may contain errors. It is not medical advice. Read the original study and talk to your MS team before making decisions about treatment.
- Human efficacy
- Not established from this source
- Mechanism
- Not reported
- Evidence strength
- Limited
- Outcome
- Not reported
Why it matters
Identifying these metabolites may lead to new biomarkers that improve disease monitoring and management in MS. Understanding their roles could enhance patient care.
What this does not prove
The findings need validation in independent cohorts and do not establish causation or clinical efficacy.
Next milestone
No next milestone was established from the available source.
Study facts
- Study design
- Observational
- Participants / samples
- 323 · analyses of untargeted circulating metabolomic profiles from 541 samples of 323 people with multiple sclerosis (PwMS)
- Randomised
- Not reported
- Controlled
- Not reported
- Primary endpoint met
- Not reported
- Relevant MS type
- Not reported
- Publication date
- 2026-10-22
- Evidence reviewed
- Abstract only
- Regulatory approval
- Not reported
- Research areas
- Biomarkers
- Biological target
- p-cresol sulfate, p-cresol glucuronide, phenylacetylglutamine, carnitine-derived species, tryptophan betaine
- Pathway
- amino acid transport and metabolism
- Population
- People with multiple sclerosis, including both relapsing-remitting and progressive forms
- Size of effect
- Not reported
- Secondary endpoints
- Expanded Disability Status Scale; walking speed; manual dexterity; processing speed; Neuro-QoL patient-reported domains; optical coherence tomography-derived retinal layer thicknesses; MRI-derived measures
- MRI endpoints
- Not reported
- Biomarkers
- p-cresol sulfate; p-cresol glucuronide; phenylacetylglutamine; carnitine-derived species; tryptophan betaine; ergothioneine; N-acetylcarnosine; indolepropionate
- Safety
- Not reported
Original sources
- Primary evidenceMetabolomic Profiles Associated With Disease Severity in Multiple Sclerosis. ↗DOI: 10.1212/nxi.0000000000200664
Supporting passages (17)
speciesHuman
sample size323
subjectsHuman
sample size basisMETHODS: We conducted a cross-sectional analysis of untargeted circulating metabolomic profiles from 541 samples of 323 people with multiple sclerosis (PwMS), including both relapsing-remitting and progressive forms, detecting 332 metabolites.
research categoriesBiomarkers
publication date2026-10-22
findingsRESULTS: We identified multiple metabolites consistently associated with MS severity across clinical, patient-reported, and imaging domains.
limitationsThese candidate metabolites warrant external validation in independent cohorts and provide a rationale for future biomarker discovery studies aimed at improving disease monitoring and management in MS.
biological targetsMetabolites such as p-cresol sulfate, p-cresol glucuronide, phenylacetylglutamine, and carnitine-derived species were linked to greater disease severity, whereas tryptophan betaine, ergothioneine, N-acetylcarnosine, and indolepropionate were associated with more favorable outcomes.
pathwayamino acid transport and metabolism
populationMETHODS: We conducted a cross-sectional analysis of untargeted circulating metabolomic profiles from 541 samples of 323 people with multiple sclerosis (PwMS), including both relapsing-remitting and progressive forms, detecting 332 metabolites.
secondary endpointsAssociations between metabolite levels and outcomes, including clinical disability (Expanded Disability Status Scale), functional tests (walking speed, manual dexterity, and processing speed), Neuro-QoL patient-reported domains, optical coherence tomography-derived retinal layer thicknesses, and MRI-derived measures, were assessed using linear mixed-effects models adjusted for age, sex, race, treatment status, and MS subtype.
biomarkersMetabolites such as p-cresol sulfate, p-cresol glucuronide, phenylacetylglutamine, and carnitine-derived species were linked to greater disease severity, whereas tryptophan betaine, ergothioneine, N-acetylcarnosine, and indolepropionate were associated with more favorable outcomes.
peer reviewedPublication types: Journal Article
subjectsMeSH terms: Humans; Female; Male; Cross-Sectional Studies; Severity of Illness Index; Adult; Biomarkers; Middle Aged; Metabolomics; Multiple Sclerosis, Relapsing-Remitting; Metabolome; Multiple Sclerosis; Multiple Sclerosis, Chronic Progressive
study designMeSH terms: Humans; Female; Male; Cross-Sectional Studies; Severity of Illness Index; Adult; Biomarkers; Middle Aged; Metabolomics; Multiple Sclerosis, Relapsing-Remitting; Metabolome; Multiple Sclerosis; Multiple Sclerosis, Chronic Progressive
research categoriesMeSH terms: Humans; Female; Male; Cross-Sectional Studies; Severity of Illness Index; Adult; Biomarkers; Middle Aged; Metabolomics; Multiple Sclerosis, Relapsing-Remitting; Metabolome; Multiple Sclerosis; Multiple Sclerosis, Chronic Progressive
AI assessment, not yet reviewed by a person · version 1 · Community votes are separate from evidence review.